BELLICUM PHARMACEUTICALS, INC (BLCM) [Rocket]

Overview

BELLICUM PHARMACEUTICALS, INC (BLCM)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Price:	$1.66			Metrics
OS:	9.5	M		-549	% ROE
Market cap:	$15.8	M
Net cash:	$7.41	M		$0.78	per share
EV:	$8.35	M

TTM Valuation
EBITDA	($30.2)	M
EBIT	($30.2)	M
EPS	($0.93)

Recent News + Filings (All items)

Date Filed	Type	Description
09/29/2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/10/2023	10-Q	Quarterly Report for the period ended June 30, 2023
07/10/2023	25-NSE	Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
06/02/2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2023	10-Q	Quarterly Report for the period ended March 31, 2023
05/05/2023	SC 13D	Form SC 13D - General statement of acquisition of beneficial ownership:
05/05/2023	3	BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 3 on BELLICUM PHARMACEUTICALS, INC

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	1.5	6.2	62.3	7.1	1.1	0.2	0.4	0.3
Revenue growth	-75.8%	-90.0%	771.6%	537.8%	505.4%	-52.3%	37.6%	-84.2%
Cost of goods sold	0.0	0.5	0.0	0.0	0.0	0.9	0.6	3.2
Gross profit	1.5	5.7	62.3	7.1	1.1	-0.7	-0.2	-2.9
Gross margin	100.0%	92.3%	100.0%	100.0%	100.0%	-367.0%	-49.5%	-1029.1%
Research and development	22.8	23.6	39.1	64.5	71.6	65.7	51.3	33.6
General and administrative	5.7	7.0	15.5	30.0	25.0	21.0	16.9	12.7
EBIT	-27.0	-24.9	-49.3	-87.4	-95.5	-87.4	-68.4	-49.2
EBIT margin	-1798.7%	-401.1%	-79.2%	-1223.1%	-8523.8%	-47230.3%	-17626.3%	-17438.7%
Pre-tax income	-25.0	-9.7	-7.7	-112.5	-98.0	-91.8	-69.2	-48.5
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-25.0	-9.7	-7.7	-112.5	-98.0	-91.8	-69.2	-48.5
Net margin	-1664.7%	-156.5%	-12.4%	-1574.6%	-8753.2%	-49610.3%	-17845.6%	-17215.6%

Diluted EPS	($0.81)	($0.84)	($1.34)	($24.01)	($24.37)	($2.89)	($2.57)	($1.84)
Shares outstanding (diluted)	30.8	11.5	5.8	4.7	4.0	31.7	27.0	26.3

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy